Chaga

Metadata

Important taxonomic note: Chaga is a fungus (Kingdom Fungi), not a plant. It is classified within the Basidiomycota alongside other medicinal mushrooms such as reishi (Ganoderma lucidum), lion’s mane (Hericium erinaceus), and turkey tail (Trametes versicolor). The term “plantFamily” in the metadata is used for consistency with the site schema but refers to its fungal family, Hymenochaetaceae.

Biological description: The chaga sclerotium appears as a large, irregular, blackened mass (resembling burnt charcoal) that protrudes from the trunk of living birch trees (Betula spp.). The outer surface is deeply cracked and black due to high melanin content; the interior is golden-brown to orange-brown with a cork-like texture. Sclerotia typically grow over 5-20 years and can reach 25-40 cm in diameter. The actual fertile fruiting body of I. obliquus is rarely observed — it forms under the bark of the host tree after the tree has died and is a resupinate (flat) structure bearing basidiospores. What is commercially harvested and traditionally used is exclusively the sclerotium.

Geographic distribution: Inonotus obliquus is found throughout the circumboreal region of the Northern Hemisphere, primarily in birch forests of Russia, Scandinavia (Finland, Norway, Sweden), the Baltic states, Poland, Canada, and the northern United States. It also occurs on birch in northern China, Korea, and Japan. The fungus parasitizes primarily Betula species (especially B. pendula and B. pubescens), causing white heart rot. It has been reported rarely on alder (Alnus), beech (Fagus), and oak (Quercus), though birch-derived sclerotia are considered pharmacologically superior due to the uptake of birch-bark triterpenoids (betulin, betulinic acid).

Approved Indications

Commission E (Germany)

• No monograph exists. Commission E has never assessed Inonotus obliquus. Chaga was not part of the German or broader European phytotherapy tradition evaluated during the Commission E monograph program (1978-1994).

ESCOP (European Scientific Cooperative on Phytotherapy)

• No monograph exists. ESCOP has not assessed chaga for any indication.

EMA/HMPC (European Medicines Agency)

• No assessment report or monograph exists. The HMPC has not evaluated Inonotus obliquus under either the well-established use or traditional use pathways. Chaga does not appear in the EU Community Herbal Monograph program.

Russian Pharmacopoeia (Historical Status)

• Chaga holds a unique position in Russian pharmaceutical history. In 1955, the USSR Ministry of Health officially recognized Inonotus obliquus as a medicinal substance and included it in the Soviet Pharmacopoeia under the preparation name Befungin (Befunginum).
• Befungin is an alcohol-based extract of chaga sclerotium, combined with cobalt salts, that was registered for the treatment of gastritis, gastric and duodenal ulcers, gastric polyposis, and as a symptomatic agent in oncology patients (to improve general condition and appetite, not as an anti-cancer treatment per se).
• Befungin remains available as an over-the-counter preparation in Russia and several former Soviet states to the present day.
• Critical note: The Soviet-era registration of Befungin was based on traditional use rationale and limited observational data, not on randomized controlled trials meeting modern evidence-based medicine criteria. No clinical trial data supporting Befungin’s efficacy has been published in peer-reviewed, internationally indexed journals.

Agreement/Disagreement Analysis

There is a notable disconnect between regulatory and commercial realities:

• No Western regulatory body (Commission E, ESCOP, EMA, FDA, Health Canada, TGA) has approved or positively assessed chaga for any therapeutic indication.
• The Russian Pharmacopoeia historically recognized Befungin, but this recognition predated modern clinical trial methodology.
• Health Canada permits chaga as a Natural Health Product ingredient with the limited claim “source of fungal polysaccharides with immunomodulating properties” and recommends a maximum daily intake of 3.6 g of raw material.
• The US FDA has not evaluated chaga for any therapeutic claim; it is sold as a dietary supplement under DSHEA.
• Consumer market reality stands in stark contrast to the evidence base: chaga is marketed globally with extensive health claims (anti-cancer, immune-boosting, anti-aging) that far outstrip the available scientific evidence.

Conditions Treated

Primary — No Conditions with Clinical Trial Evidence

There are no human conditions for which chaga has demonstrated efficacy in published randomized controlled trials. This is the central fact of the chaga evidence base and must be emphasized. Despite widespread marketing claims and consumer popularity, chaga has the weakest clinical evidence profile among the commonly sold medicinal mushrooms (weaker than reishi, lion’s mane, cordyceps, and turkey tail, all of which have at least some human trial data).

Secondary — Preclinical Evidence Only

Immune Support (In Vitro and Animal Studies)

• Chaga polysaccharides activate macrophages via Toll-like receptor 2 (TLR2) and TLR4 signaling, with weaker agonism at Dectin-1 receptors. In vitro studies demonstrate secretion of nitric oxide, TNF-alpha, and IL-6 from treated macrophages.
• When combined with interferon-gamma, chaga polysaccharides stimulate production of IL-12p70, a key cytokine in anti-tumor immunity, and induce macrophage-mediated inhibition of cancer cell growth in cell culture and mouse models.
• Beta-glucans from chaga enhance NK cell activity and promote dendritic cell maturation in animal models.

Antioxidant Activity (In Vitro)

• Chaga extracts demonstrate high antioxidant capacity in standard in vitro assays (DPPH, ABTS, FRAP). The melanin complex, polyphenolic compounds, and superoxide dismutase (SOD) content all contribute to this activity.
• Melanin constitutes up to approximately 30% of the sclerotium dry weight and is a potent scavenger of reactive oxygen species.
• Caveat: In vitro antioxidant assays (including ORAC values) do not reliably predict in vivo antioxidant effects in humans. The frequently cited claim that chaga has the “highest ORAC score of any natural food” lacks verifiable sourcing and should be treated with skepticism.

Anti-inflammatory Activity (Animal Studies)

• Inotodiol, lanosterol, and trametenolic acid (lanostane-type triterpenoids) from chaga inhibit NF-kB/p65 signaling and reduce pro-inflammatory cytokine production in LPS-stimulated macrophage models (RAW 264.7 cells).
• Oral administration of chaga extract inhibited LPS-induced NF-kB activation in a mouse model.
• Inotodiol (the most abundant triterpenoid, at approximately 0.2% of dry weight) has been evaluated as an anti-inflammatory agent in animal models, showing reductions in edema and inflammatory markers.

Cytotoxic / Anti-tumor Activity (In Vitro)

• Betulinic acid demonstrates direct cytotoxicity against multiple cancer cell lines through mitochondrial-mediated apoptosis induction.
• Chaga polysaccharides and triterpenoids have shown anti-proliferative activity against colorectal (HCT-116), breast, lung (A549), and hepatoma cell lines in vitro.
• A 2025 network pharmacology study identified 26 bioactive compounds from chaga and 244 potential anti-cancer targets, with AKT1, IFNG, and MMP9 as core targets.
• No in vivo anti-tumor efficacy has been demonstrated in humans.

Antiviral Activity (In Vitro)

• Water extracts of chaga have shown inhibitory activity against herpes simplex virus type 1 (HSV-1) in Vero cell culture at IC50 approximately 3.82 micrograms/mL, through prevention of viral entry and inhibition of virus-induced membrane fusion.
• Chaga extract at 2.5 micrograms/mL inhibited HIV-1 protease by 50% in vitro.
• Melanin-containing fractions demonstrated activity against influenza A (pandemic H1N1 strain) with IC50 values of 10-40 micrograms/mL.
• None of these antiviral effects have been demonstrated in human subjects.

Anti-diabetic Activity (Animal Studies)

• Chaga polysaccharides reduced postprandial blood glucose in diabetic mouse models by inhibiting alpha-amylase and alpha-glucosidase activity.
• A 2025 bioinformatics study proposed anti-diabetic mechanisms via PI3K/Akt, Ras, RAP1, and MAPK signaling pathways.
• Betulinic acid showed hypoglycemic effects and reduced body weight in high-fat diet-induced obese mice.

Traditional Uses — Russian, Siberian, and Northern European Folk Medicine

Historical Context

• The Khanty people of Western Siberia were among the first documented users of chaga, likely as early as the 12th century. They used crushed sclerotium as a decoction, by inhalation of smoke from burned material, and as a topical wash (macerated in water and used as antiseptic soap).
• Kievan Rus chronicle (12th century): A frequently cited historical account states that Grand Prince Vladimir Monomakh (1053-1125) was treated for a lip tumor with chaga decoction. The historical accuracy of this account is debated, but it illustrates the antiquity of chaga use in the East Slavic tradition.
• In Finland, chaga was used as a coffee substitute during World War II, and the Finnish word pakuri remains common. Decoctions were used as a folk remedy for stomach complaints and tuberculosis.
• Alexander Solzhenitsyn popularized chaga in Western awareness through his 1967 novel Cancer Ward, in which a character describes the observation that peasants in certain Russian regions who drank chaga tea had lower cancer rates.

Traditional Indications (Folk Medicine)

• Gastrointestinal disorders: Gastritis, gastric ulcers, duodenal ulcers, and gastric polyps (the primary traditional indications codified in the Soviet Pharmacopoeia as Befungin)
• Cancer: Used as a general folk remedy for tumors and malignancies, particularly stomach and colorectal cancers, across Russian, Polish, and Baltic folk medicine traditions
• Tuberculosis: The Khanty people and Siberian folk practitioners used chaga preparations for pulmonary tuberculosis
• General tonic: Consumed as a daily beverage (tea/decoction) for overall health maintenance and vitality, particularly in Siberian communities
• Cardiovascular and hepatic conditions: Traditional use for heart and liver diseases reported among the Khanty and other Siberian peoples
• Parasitic infections: Used as an anthelminthic (against intestinal worms) in Khanty traditional medicine
• Topical antiseptic: Burned chaga ash macerated in water and used for skin washing

Mechanism of Action

The pharmacological profile of chaga involves multiple compound classes acting through distinct mechanisms. All mechanistic data described below is derived from in vitro cell culture and animal model studies. No pharmacokinetic or pharmacodynamic data from human studies exists.

1. Beta-Glucan Polysaccharide Immune Stimulation

Chaga contains water-soluble polysaccharides, primarily beta-(1,3)-D-glucans with (1,6) branching. Two well-characterized polysaccharide fractions (designated AcF1 and AcF3 in research literature) activate innate immune cells through pattern recognition receptors:

• TLR2 and TLR4 agonism (strong): These polysaccharides are potent agonists of Toll-like receptors 2 and 4 on macrophages, triggering MyD88-dependent signaling cascades that lead to NF-kB activation and secretion of pro-inflammatory cytokines (TNF-alpha, IL-6, nitric oxide).
• Dectin-1 agonism (weak): Unlike the beta-glucans of some other medicinal mushrooms, chaga polysaccharides are only weak agonists of Dectin-1, the C-type lectin receptor primarily responsible for recognizing fungal beta-glucans.
• IL-12p70 production: In combination with interferon-gamma priming, chaga polysaccharides stimulate macrophage production of IL-12p70, a critical cytokine that bridges innate and adaptive immunity and drives Th1-type anti-tumor immune responses.
• Downstream effects: Enhanced macrophage phagocytosis, increased NK cell cytotoxicity, and promotion of dendritic cell maturation have been demonstrated in animal models.

2. Betulinic Acid Cytotoxicity

Betulin and betulinic acid are pentacyclic triterpenoids that chaga concentrates from the birch bark substrate. Betulinic acid is not synthesized by the fungus itself but is absorbed from the host tree, which is why birch-grown chaga is considered pharmacologically distinct from chaga growing on other tree species.

• Mitochondrial apoptosis pathway: Betulinic acid triggers apoptosis in cancer cells through a direct effect on mitochondrial membranes, inducing cytochrome c release and caspase activation. This pathway is selective for cancer cells in vitro, with relatively lower toxicity to normal cells.
• Metabolic effects: Betulinic acid inhibits alpha-amylase (reducing carbohydrate absorption), promotes insulin and leptin secretion, and has demonstrated hypoglycemic and anti-obesity effects in animal models.

3. Melanin Complex Antioxidant Activity

The black exterior of the chaga sclerotium is rich in melanin pigments, which constitute up to approximately 30% of dry weight. Chaga melanin is a complex of fungal and birch-derived melanin subunits:

• Radical scavenging: Melanin acts as a broad-spectrum free radical scavenger, neutralizing superoxide, hydroxyl, and peroxyl radicals.
• Superoxide dismutase (SOD): Chaga contains substantial quantities of SOD enzyme, which catalyzes the dismutation of superoxide anion radicals into oxygen and hydrogen peroxide. Claims that chaga contains “50 times more SOD than other medicinal mushrooms” appear in commercial literature but lack rigorous comparative verification. [UNCERTAIN]
• UV protection: Melanin absorbs UV radiation, which may explain the sclerotium’s ecological function (protecting exposed fungal tissue) but has no established relevance to human oral consumption.

4. Triterpenoid Anti-inflammatory Activity

Chaga contains multiple lanostane-type triterpenoids, including inotodiol (the most abundant, approximately 0.2% of dry weight), lanosterol, trametenolic acid, and ergosterol:

• NF-kB inhibition: These triterpenoids inhibit NF-kB nuclear translocation and downstream pro-inflammatory cytokine production. In RAW 264.7 macrophage models, the petroleum ether and ethyl acetate fractions of chaga significantly inhibited NO production and NF-kB luciferase activity.
• Inotodiol immunomodulation: Inotodiol has been shown to induce atypical maturation in dendritic cells, suggesting a nuanced immunomodulatory (rather than purely immunostimulatory) activity that differs from the polysaccharide-driven immune activation.
• Anti-tumor promoting activity: Inotodiol, lanosterol, trametenolic acid, and 3-beta,22-dihydroxylanosta-7,9(11),24-triene have demonstrated anti-tumor promoting activity in in vitro assays.

5. Polyphenol Antioxidant Activity

Chaga contains diverse polyphenolic compounds that contribute additional antioxidant capacity through hydrogen atom transfer and single electron transfer mechanisms. These polyphenols appear to offer the strongest protection against oxidative stress in in vitro antioxidant assays, though the clinical significance for human oral consumption is unestablished.

Clinical Evidence Summary

Human Clinical Trials

There are no published randomized, double-blind, placebo-controlled clinical trials of chaga (Inonotus obliquus) in humans for any indication. This statement, current as of February 2026, is the single most important fact in this monograph.

A 2021 review titled “Inonotus obliquus — from folk medicine to clinical use” (Szychowski et al., published in Journal of Traditional and Complementary Medicine) noted that while the therapeutic effects of chaga components are well characterized in vitro, the effects in vivo in humans are not described in detail. The authors concluded that studies meeting evidence-based medicine (EBM) criteria are needed.

A 2024 review (Kaczmarczyk-Ziemba et al., published in Mycology) confirmed extensive preclinical evidence for anti-inflammatory, antioxidant, anticancer, anti-diabetic, anti-obesity, hepatoprotective, renoprotective, anti-fatigue, antibacterial, and antiviral activities, but noted the absence of rigorous clinical data.

Preclinical Evidence Summary

Comparison with Other Medicinal Mushrooms

Chaga’s evidence gap becomes especially clear when compared with related species:

• Reishi (Ganoderma lucidum): A Cochrane systematic review of five RCTs exists for cancer adjunctive therapy. Multiple clinical trials for immune modulation and quality of life.
• Lion’s Mane (Hericium erinaceus): Published RCTs for cognitive function (Mori et al., 2009) and depressive symptoms.
• Cordyceps (C. militaris / O. sinensis): Multiple small RCTs for exercise performance and VO2 max improvement.
• Turkey Tail (Trametes versicolor): PSK/PSP polysaccharide extracts have been used in Japanese oncology with clinical trial support and are approved as adjunctive cancer therapy in Japan.
• Chaga: Zero human clinical trials for any indication.

Evidence Limitations

• All positive pharmacological data comes from in vitro cell culture or animal models, which have a poor historical track record of translating to human therapeutic effects.
• Bioavailability of key compounds (betulinic acid, beta-glucans, inotodiol) from oral chaga preparations in humans has not been characterized.
• The wide variety of chaga preparation methods (decoction, hot-water extract, ethanol extract, dual extract, raw powder) means that chemical composition varies enormously between products, making any future translation of preclinical findings to specific consumer products highly uncertain.
• Marketing claims for chaga routinely far exceed the evidence, particularly for cancer prevention, immune boosting, and anti-aging.

Safety Profile

General Assessment

Chaga has a long history of traditional use as a tea or decoction in Russian, Scandinavian, and Northern European communities without widespread reports of acute toxicity. However, systematic safety data from controlled human studies is absent. The primary documented safety concern is oxalate nephropathy, which has been reported in multiple case reports.

Oxalate Nephropathy Risk (Case Reports)

This is the most serious documented adverse effect of chaga consumption and warrants detailed attention:

Case 1 (Kikuchi et al., 2014 — Japan): A 72-year-old Japanese woman with hepatocellular carcinoma developed oxalate nephropathy after consuming chaga mushroom powder (4-5 teaspoons per day) for 6 months. Kidney biopsy showed calcium oxalate crystal deposits in the renal tubules. This was the first published case of chaga-induced oxalate nephropathy. [PMID: 23149251]

Case 2 (Lee et al., 2020 — South Korea): A 49-year-old Korean man developed end-stage renal disease after long-term ingestion of chaga mushroom powder for atopic dermatitis. Kidney biopsy showed chronic tubulointerstitial nephritis with oxalate crystal deposits. Analysis revealed that the chaga mushroom used had an extremely high oxalate content of 14.2 g per 100 g of dry material. The patient required long-term dialysis. [PMID: 32419395]

Case 3 (Kim et al., 2022 — South Korea): A 69-year-old Korean man who had been consuming chaga mushroom powder at 10-15 g per day for 3 months presented with generalized edema and oliguria. He developed acute oxalate nephropathy with nephrotic syndrome. Renal function recovered after hemodialysis and high-dose steroid therapy. [PMID: 35451393]

Mechanism: Chaga sclerotium contains very high concentrations of oxalic acid. Excessive oral intake leads to hyperoxaluria and deposition of calcium oxalate crystals in the renal tubules, causing acute tubular injury, interstitial inflammation, and potentially irreversible renal fibrosis.

Risk factors: Pre-existing kidney disease, prolonged use at high doses (greater than approximately 3.6 g/day), dehydration, and concurrent use of other high-oxalate foods or supplements.

Drug Interactions

Side Effects

• At traditional doses (tea/decoction): No systematic side effect data exists. Traditional use over centuries suggests reasonable tolerability at conventional tea-preparation doses.
• At supplement doses: Mild gastrointestinal discomfort (nausea, bloating, diarrhea) has been anecdotally reported but not systematically studied.
• Allergic reactions: Possible in individuals with sensitivities to fungi or molds. Cross-reactivity with other Hymenochaetaceae species is theoretically possible.
• Oxalate-related effects: Beyond overt nephropathy (described above), chronic moderate oxalate intake from chaga may contribute to kidney stone formation in susceptible individuals.

Pregnancy and Lactation

• Pregnancy Category: Unknown. No human data. No animal reproductive toxicity studies published. Traditional sources do not specifically address pregnancy. Given the absence of safety data, chaga should be avoided during pregnancy.
• Lactation: No data. Avoid use during breastfeeding until safety is established.

Contraindications

• Active kidney disease or history of kidney stones: Due to high oxalate content, chaga is contraindicated in individuals with chronic kidney disease, oxalate nephropathy, or a history of calcium oxalate kidney stones.
• Anticoagulant therapy: Use with caution or avoid in patients on warfarin or other anticoagulants due to theoretical increased bleeding risk. If used concurrently, INR should be monitored.
• Autoimmune conditions: The immunostimulatory properties of chaga beta-glucans theoretically could exacerbate autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease). Use with caution or avoid.
• Pre-surgical: Discontinue at least 2 weeks before elective surgery due to theoretical antiplatelet activity.

Clinical Dosage

Important Caveat

Because no human clinical trials exist, there are no evidence-based dosage recommendations for chaga. All dosage information below is derived from traditional use, the Russian Pharmacopoeia (Befungin), Health Canada guidance, and manufacturer recommendations. Optimal dosing for any specific health outcome is entirely unknown.

Traditional Preparation (Decoction/Tea)

• Method: Dried chaga chunks are simmered in water (not boiling — traditionally kept below 80 degrees C to preserve heat-sensitive compounds) for 1-4 hours, producing a dark brown decoction.
• Traditional dose: 1-3 cups per day of decoction prepared from approximately 5-10 g of dried chaga.
• Siberian folk practice: Chaga chunks were reused for multiple decoctions until the liquid no longer darkened.

Befungin (Russian Pharmacopoeia Preparation)

• Formulation: Alcohol-based concentrated extract of chaga with added cobalt chloride and cobalt sulfate.
• Dose: 3 tablespoons of Befungin diluted in 150 mL of warm water, taken 3 times daily before meals (per Russian labeling).
• Duration: Courses of 3-5 months with breaks between courses were traditionally recommended.

Modern Supplement Forms

• Dried powder: 1,000-3,000 mg per day (capsules or powder), divided into 1-3 doses. Health Canada suggests not exceeding 3.6 g per day of raw chaga material.
• Hot-water extract: 300-1,000 mg per day of concentrated extract, depending on extraction ratio.
• Dual extract (water + ethanol): 1-3 mL of tincture, 1-3 times daily (extraction ratios vary widely between manufacturers).
• Standardization: High-quality extracts may be standardized to beta-glucan content (target approximately 20-30% polysaccharides) or total triterpenoid content. However, there is no consensus standardization framework for chaga products, and product quality varies enormously.

Extraction Considerations

• Hot-water extraction is necessary to release beta-glucan polysaccharides from the chitin cell wall matrix. Raw, unextracted chaga powder delivers significantly fewer bioavailable polysaccharides.
• Ethanol extraction captures alcohol-soluble triterpenoids (inotodiol, betulinic acid, lanosterol) that are poorly extracted by water alone.
• Dual extraction (sequential water and ethanol extraction) theoretically provides the broadest spectrum of bioactive compounds, though no human studies have compared the efficacy of different extraction methods.

Sources

• Szychowski KA, Skora B, Pomianek T, Gminski J. Inonotus obliquus — from folk medicine to clinical use. J Tradit Complement Med. 2021;11(4):293-302. PMID: 34195023
• Kaczmarczyk-Ziemba A, Kijowska I, Przybyla M. Therapeutic properties of Inonotus obliquus (Chaga mushroom): A review. Mycology. 2024;15(2):160-178. PMC11132974
• Glamoclija J, Cirkovic Velickovic T, Petrovic J. A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms. Heliyon. 2024;10(16):e35665. PMC11336990
• Gery A, Dubreule C, Andre V, et al. Chaga (Inonotus obliquus), a future potential medicinal fungus in oncology? A chemical study and a comparison of the cytotoxicity against human lung adenocarcinoma cells (A549) and human bronchial epithelial cells (BEAS-2B). Integr Cancer Ther. 2018;17(3):832-843. PMC6142110
• Arata S, Watanabe J, Maeda M, et al. Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice. Heliyon. 2016;2(5):e00111
• Kikuchi Y, Seta K, Ogawa Y, et al. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol. 2014;81(6):440-444. PMID: 23149251
• Lee SS, Lee S, Lee SH, et al. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122. PMID: 32419395
• Kim YR, Park YJ, Jang HR. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine. 2022;101(10):e29010. PMID: 35451393
• Tian J, Hu X, Liu D, et al. Identification of Inonotus obliquus polysaccharide with broad-spectrum antiviral activity against multi-feline viruses. Int J Biol Macromol. 2017;95:160-167
• Pan HH, Yu XT, Li T, et al. Aqueous extract from a Chaga medicinal mushroom, Inonotus obliquus (higher Basidiomycetes), prevents herpes simplex virus entry through inhibition of viral-induced membrane fusion. Int J Med Mushrooms. 2013;15(1):29-38. PMID: 25069286
• Giridharan VV, Thandavarayan RA, Konishi T. Evaluation of toxicity and efficacy of inotodiol as an anti-inflammatory agent using animal model. Molecules. 2022;27(15):4704. PMC9331631
• Wold CW, Gerber H, Engstad RE, Inngjerdingen KT. Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce macrophage anti-cancer activity. Commun Biol. 2024;7:222. PMC10891174
• Van Q, Nayak BN, Reimer M, et al. Anti-inflammatory effect of Inonotus obliquus, Polygala senega L., and Viburnum trilobum in a cell screening assay. J Ethnopharmacol. 2009;125(3):487-493
• Shashkina MYa, Shashkin PN, Sergeev AV. Chemical and medicobiological properties of chaga (review). Pharm Chem J. 2006;40:560-568
• Shikov AN, Pozharitskaya ON, Makarov VG, et al. Medicinal plants of the Russian Pharmacopoeia; their history and applications. J Ethnopharmacol. 2014;154(3):481-536
• Zhong XH, Ren K, Lu SJ, et al. Progress of research on Inonotus obliquus. Chin J Integr Med. 2009;15(2):156-160. PMID: 19407959
• Memorial Sloan Kettering Cancer Center: Chaga Mushroom monograph (mskcc.org, accessed February 2026)
• Natural Medicines Comprehensive Database: Chaga monograph (accessed February 2026)

Connections

• Reishi (Ganoderma lucidum): The closest comparator among medicinal mushrooms. Both contain immunomodulatory beta-glucan polysaccharides and bioactive triterpenoids. However, reishi has clinical trial evidence (Cochrane review for cancer adjunctive therapy) that chaga entirely lacks. Reishi triterpenoids (ganoderic acids) differ structurally from chaga triterpenoids (inotodiol, lanosterol).
• Lion’s Mane (Hericium erinaceus): Another medicinal mushroom with superior clinical evidence (RCTs for cognitive function). Lion’s mane’s primary mechanism (nerve growth factor stimulation via hericenones and erinacines) is completely different from chaga’s profile.
• Cordyceps (Cordyceps militaris / Ophiocordyceps sinensis): Shares the medicinal mushroom category and beta-glucan immune modulation, but cordyceps has a distinct adenosine-analog pharmacology (cordycepin) and published RCTs for exercise performance.
• Astragalus (Astragalus membranaceus): A traditional immune tonic from Chinese medicine with polysaccharide-mediated immune stimulation similar in broad mechanism to chaga beta-glucans. Astragalus has more clinical trial data (though still limited) and a more established regulatory profile.
• Birch Bark (Betula spp.): The source tree for chaga’s betulin and betulinic acid content. Birch bark itself has a separate phytotherapy tradition, and understanding the birch-chaga relationship is essential for appreciating why host tree species matters for chaga’s chemical profile. Betulinic acid is a birch-derived compound that chaga concentrates rather than synthesizes de novo.
• Turkey Tail (Trametes versicolor): PSK and PSP polysaccharide extracts from turkey tail represent the most clinically validated mushroom-derived immunomodulators, with approval as adjunctive cancer therapy in Japan. This provides a useful benchmark for what clinical validation of mushroom polysaccharides looks like — and what chaga has not achieved.